Menu

What is NAION, the rare eye condition linked to GLP-1 drugs?

Watch to understand the emerging safety concerns, clinical evidence and changing debate around access to obesity medicines.

Published Nov 16, 2026 | 1:30 PM ⚊ Updated Nov 16, 2026 | 1:30 PM

GLP-1 medicines such as Ozempic, Wegovy and Mounjaro are transforming diabetes and obesity treatment. But emerging safety concerns and questions over who should prescribe these medicines are bringing them under greater scrutiny.

In this South First explainer, Sumit Jha looks at two important developments:

● FDA safety warning: What is NAION, the rare eye condition associated with a potential increased risk among GLP-1 users? We explain its symptoms, risk factors, the FDA’s findings and what patients should watch out for.
● IFSO recommendations: Should prescribing obesity medicines be limited to endocrinologists and internal medicine specialists? The International Federation for the Surgery of Obesity and Metabolic Disorders argues that prescribing eligibility should depend on doctors’ training and competence.

Watch to understand the emerging safety concerns, clinical evidence and changing debate around access to obesity medicines.

journalist-ad